Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Efficacy of AposTherapy® in Knee OA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03153956
Recruitment Status : Active, not recruiting
First Posted : May 15, 2017
Last Update Posted : May 16, 2019
Information provided by (Responsible Party):
NYU Langone Health

Brief Summary:
A prospective, interventional, randomized, double-arm clinical evaluation study to examine the efficacy of AposTherapy® versus a control group, in the short-term at 6 months and in the long-term at 12 months post-treatment, with the primary efficacy assessment based on improvement in knee pain score and improvement in function in patients following diagnosis of knee osteoarthritis (OA).

Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Device: Calibrated AposTherapy® Device: Non-Calibrated Sham Apos Therapy Device Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 92 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Phase I - A prospective, interventional, randomized, double-arm clinical evaluation of patients who have been diagnosed with OA of the knee. The active treatment arm (personally calibrated biomechanical device) will be compared to a control arm (sham-placebo device) (similar shoes without biomechanical elements).

Phase II - Open-label, cross-over study design. After the completion of phase one patients will be un-blinded to their group allocation. Patients that were allocated to the sham-placebo control group will cross to the active group and will receive the AposTherapy treatment. Patients that were allocated to the active group will continue with treatment.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized Double-Armed Efficacy Evaluation of AposTherapy® for the Treatment of Knee Osteoarthritis
Actual Study Start Date : April 16, 2015
Actual Primary Completion Date : December 7, 2018
Estimated Study Completion Date : December 7, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: Active Treatment Arm
Personally calibrated bio-mechanical device
Device: Calibrated AposTherapy®
a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.

Placebo Comparator: Control Arm
sham-placebo device (similar shoes without bio-mechanical elements).
Device: Non-Calibrated Sham Apos Therapy Device
The comparator group will receive a non-calibrated sham device.

Primary Outcome Measures :
  1. Western Ontario and McMaster University (WOMAC) score to 6 months post treatment [ Time Frame: 6 Months ]
    WOMAC evaluates the condition of patients with osteoarthritis of the knee and hip, including pain, stiffness, and physical functioning of the joints.

Secondary Outcome Measures :
  1. Visual Analog Score (VAS) score [ Time Frame: 12 Months ]
    The visual analogue scale or visual analog scale (VAS) is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured.

  2. Short-Form 36 (SF-36) score [ Time Frame: 6 Months ]
    The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health at pre-treatment and following 3 months and 6 months post-treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients suffering from symptomatic unilateral or bilateral knee OA at the medial compartment for at least six months;
  • Fulfilling the ACR clinical criteria;
  • Having radiographically assessed OA of the knee with a Kellgren-Lawrence grade more than or equal to grade 2; and,
  • Having VAS-Pain ≥ 3, on a scale between 0-10.
  • Patients who have a shoe size between US 4 and US 12

Exclusion Criteria:

  • Patients suffering from acute septic arthritis.
  • Patients who received a corticosteroid injection within 3 months of the study.
  • Patients who received hyaluronic acid (HA) injections within 6 months of the study
  • Patients suffering from avascular necrosis of the knee.
  • Patients with a history of knee buckling or recent knee injury.
  • Patients who have had a joint replacement or other major surgery to the knee, hip or ankle (ipsilateral or contralateral side).
  • Patients suffering from neuropathic arthropathy.
  • Patients with an increased tendency to fall.
  • Patients exhibiting a lack of physical or mental ability to perform or comply with the study procedure.
  • Patients with a history of pathological osteoporotic fracture.
  • Patients suffering from symptomatic degenerative arthritis in lower limb joints other than the knees.
  • Patients with referred pain in the knees from primary back or hip joint pain.
  • Patients with neurological deficits to the lower extremity (ex. foot drop)
  • Patients whose shoe size is less than US 4 and greater than US 12
  • Patients who have had arthroscopy within 6 months of the study
  • Patients with inflammatory arthropathy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03153956

Layout table for location information
United States, New York
New York University School of Medicine
New York, New York, United States, 10016
Sponsors and Collaborators
NYU Langone Health
Layout table for investigator information
Principal Investigator: Dennis Cardone, DO NYU Langone Health

Layout table for additonal information
Responsible Party: NYU Langone Health Identifier: NCT03153956    
Other Study ID Numbers: 14-02127
First Posted: May 15, 2017    Key Record Dates
Last Update Posted: May 16, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by NYU Langone Health:
AposTherapy® System
Total knee arthroplasties
Degenerative joint disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases